Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Fexofenadine HCl Coated tablet
Fexofenadine Coated · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment Sequence Group 1 | EXPERIMENTAL | - |
| Treatment Sequence Group 2 | EXPERIMENTAL | - |
| Treatment Sequence Group 3 | EXPERIMENTAL | - |
| Treatment Sequence Group 4 | EXPERIMENTAL | - |
| Treatment Sequence Group 5 | EXPERIMENTAL | - |
| Treatment Sequence Group 6 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Fexofenadine HCl Coated tablet | DRUG | Film-coated tablet. |
| Fexofenadine HCl New Formulation Tablet | DRUG | New formulation tablet. |
Inclusion Criteria: 1. Male or female non-smokers (no use of tobacco or nicotine products within 3 months prior to screening), ≥18 and ≤55 years of age, with body-mass-index (BMI) \>18 and \<29.9 kilogram per meter square (kg/m\^2) and body weight ≥50.0 kg to ≤100.0 kg for males and ≥40.0 kg to ≤90...
Fexofenadine Coated is an investigational small molecule formulation developed by Sanofi. It is a coated tablet version of fexofenadine HCl that has been studied in healthy adult volunteers. The specific therapeutic indication for this coated formulation has not been disclosed.
Fexofenadine Coated targets HRH1, the histamine H1 receptor, and acts as an antagonist at this receptor. By blocking HRH1, the drug interferes with histamine signaling at the receptor level. This target class is consistent with the antihistamine activity associated with fexofenadine.
Fexofenadine Coated is developed by Sanofi, which trades under the ticker SNY. Sanofi is the sponsor behind the clinical development of this coated tablet formulation of fexofenadine HCl.
Fexofenadine Coated is in Phase 1 clinical development. It is an investigational formulation and is not approved. The Phase 1 program consists of one completed trial, with no active trials currently listed.
Fexofenadine Coated has been evaluated in one completed Phase 1 trial, NCT06284902, titled Bioavailability Study of Fexofenadine HCl New Formulation Tablet. The trial enrolled 25 healthy adult volunteers in Canada, used a randomized controlled design, and included both male and female participants aged 18 years and older.
Yes, Fexofenadine Coated is also known as Fexofenadine HCl Coated tablet. Both names refer to the same Sanofi investigational product, a coated tablet formulation of fexofenadine HCl that has been studied in a Phase 1 bioavailability trial.